Voxilaprevir intermediate 4(also known as GS9857 Intermediate 4) is a pharmaceutical intermediate for the synthesis of the Voxilaprevir, which is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor. It is also used as intermedates for various pharmceuticals, such as Glecaprevir, Grazoprevir, Simeprevir and Ruzasvir, etc..
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.[1]
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.[2]
Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.[3]
References:
[1] E.J.Gane, et al, Gastroenterology, 2016, 151(5), pp 902-909.
[2] M.Bourliere, et al, N. Engl. J. Med., 2017, 376(22), pp 2134-2146.
[3] G.Camus, et al, Virology, 2018, 514, pp 134-141.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not classified as a dangerous goods
NONH for all modes of transport
1. Product Specification
Available on request.
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email tosales@kumidas.com.
-1-amino-2-(difluoromethyl)-N-(1-methylcyclopropyl)sulfonylcyclopropane-1-carboxamide_hydrochloride.png)